Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Dianthus Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- +4 vs. Q4 2024
- Shares held
- 37.7M
- +2.65M (+7.6%) vs. Q4 2024
- Total value
- $685.5M
- −$78.8M (−10.3%) vs. Q4 2024
- New holders
- 16
- 29 more added
- Sold out
- 12
- 31 more reduced
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DNTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 269 | $6.40B |
| Q1 2026 | 241 | $5.18B |
| Q4 2025 | 166 | $2.02B |
| Q3 2025 | 140 | $1.84B |
| Q2 2025 | 103 | $728.6M |
| Q1 2025 | 99 | $685.5M |
| Q4 2024 | 96 | $765.7M |
| Q3 2024 | 91 | $858.7M |
| Q2 2024 | 74 | $768.8M |
| Q1 2024 | 76 | $782.3M |
| Q4 2023 | 39 | $106.5M |
| Q3 2023 | 30 | $136.3M |
| Q2 2023 | 46 | $22.0M |
| Q1 2023 | 52 | $23.6M |
| Q4 2022 | 54 | $11.1M |
| Q3 2022 | 72 | $65.8M |
| Q2 2022 | 75 | $54.6M |
| Q1 2022 | 93 | $138.9M |
| Q4 2021 | 94 | $211.4M |
| Q3 2021 | 93 | $276.0M |
| Q2 2021 | 97 | $366.3M |
| Q1 2021 | 90 | $418.4M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Dianthus Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Millennium Management LLC | 0 | $0 | 0.00% | −90,436−100.0% | Sold out |
| Allostery Investments LP | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Swiss National Bank | 0 | $0 | 0.00% | −14,400−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −10,601−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −4,197−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −3,025−100.0% | Sold out |
| KBC Group NV | 0 | $0 | 0.00% | −1,593−100.0% | Sold out |
| KLP Kapitalforvaltning AS | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −1,200−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |